Ester Judith Herrmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ester Judith Herrmann has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Birgit Assmus
Cardiology, Department of Medicine I, University Hospital Giessen and Marburg, Justus Liebig University Giessen , Giessen
7 shared publications A. M. Zeiher
Med. Klinik III, Kardiologie, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland
2 shared publications- Christian W. Hamm
Department of Medicine I, Cardiology and Angiology, University Hospital Giessen and Marburg, 35392 Giessen, Germany
2 shared publications - Khodr Tello
Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC) Member of the German Center for Lung Research (DZL) Giessen Germany
2 shared publications S. Fichtlscherer
Med. Klinik III, Kardiologie, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland
2 shared publications- Samuel Sossalla
Department of Cardiology and Angiology, University of Giessen & Kerckhoff Heart Center, Bad Nauheim/DZHK (Partner Site RheinMain), Germany (S.S.).
2 shared publications
Latest Publications
- 29 April 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (1) , 264-268
Association between preoperative hold time of SGLT2 inhibitors and postoperative blood ketone concentration: an interim analysis of a multicentre prospective cohort study
- 29 April 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (1) , 264-268
Association between preoperative hold time of SGLT2 inhibitors and postoperative blood ketone concentration: an interim analysis of a multicentre prospective cohort study
- Open Access
- 14 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1469
A Word of Caution—Potential Limitations of Pulmonary Artery Pressure Monitoring in Detecting Congestion Caused by Right-Sided Heart Failure
Background/Objectives: Patients with New York Heart Association (NYHA) class III heart failure (HF) suffer from frequent hospitalizations. Non-invasive pulmonary artery pressure (PAP) sensor-guided HF care has been shown to reduce hospitalizations. However, it is unknown whether the PAP changes prior to hospitalization differ between clinical right, left or global cardiac decompensation. Methods: Sensor-derived PAP data and HF hospitalization records from 41 patients with NYHA class III HF were classified retrospectively into predominantly left, right or global decompensation. Linear mixed-effect regression models were used for statistical evaluations of the PAP in selected hospitalizations for which admission was at least 28 days after the last admission and 14 days after the last hospital discharge and with readings in between. Results: During 24.4 months of follow-up, 127 hospitalizations in 38 patients were evaluated. The global cardiac decompensation (n = 13) had the highest PAP before hospitalization, followed by left-sided (n = 20) decompensation. Patients with right-sided decompensation (n = 9) had comparable PAP values before hospitalization to the cohort without any cardiac decompensation (n = 85). The diastolic PAP showed a significant increase of 0.035 mmHg/day (p = 0.0097) in left-sided decompensation and of 0.13 mmHg/day (p < 0.0001) in global cardiac decompensation, whereas no significant change in the diastolic PAP occurred prior to the right-sided decompensation. The baseline right ventricular function and right ventricle–pulmonary arterial coupling (TAPSE/PASP ratio) were impaired in patients with subsequent global cardiac decompensation. Conclusion: PAP telemonitoring-guided therapy can reliably detect early signs of left and global cardiac decompensation but may be limited in detecting right-sided cardiac congestion. The routine assessment of RV–PA coupling may improve the detection of global cardiac decompensation, as severe impairments could indicate impending deterioration. In contrast, monitoring the RV contractility may aid in identifying isolated right-sided congestion and imminent decompensation.
- 14 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1469
Open AccessA Word of Caution—Potential Limitations of Pulmonary Artery Pressure Monitoring in Detecting Congestion Caused by Right-Sided Heart Failure
Background/Objectives: Patients with New York Heart Association (NYHA) class III heart failure (HF) suffer from frequent hospitalizations. Non-invasive pulmonary artery pressure (PAP) sensor-guided HF care has been shown to reduce hospitalizations. However, it is unknown whether the PAP changes prior to hospitalization differ between clinical right, left or global cardiac decompensation. Methods: Sensor-derived PAP data and HF hospitalization records from 41 patients with NYHA class III HF were classified retrospectively into predominantly left, right or global decompensation. Linear mixed-effect regression models were used for statistical evaluations of the PAP in selected hospitalizations for which admission was at least 28 days after the last admission and 14 days after the last hospital discharge and with readings in between. Results: During 24.4 months of follow-up, 127 hospitalizations in 38 patients were evaluated. The global cardiac decompensation (n = 13) had the highest PAP before hospitalization, followed by left-sided (n = 20) decompensation. Patients with right-sided decompensation (n = 9) had comparable PAP values before hospitalization to the cohort without any cardiac decompensation (n = 85). The diastolic PAP showed a significant increase of 0.035 mmHg/day (p = 0.0097) in left-sided decompensation and of 0.13 mmHg/day (p < 0.0001) in global cardiac decompensation, whereas no significant change in the diastolic PAP occurred prior to the right-sided decompensation. The baseline right ventricular function and right ventricle–pulmonary arterial coupling (TAPSE/PASP ratio) were impaired in patients with subsequent global cardiac decompensation. Conclusion: PAP telemonitoring-guided therapy can reliably detect early signs of left and global cardiac decompensation but may be limited in detecting right-sided cardiac congestion. The routine assessment of RV–PA coupling may improve the detection of global cardiac decompensation, as severe impairments could indicate impending deterioration. In contrast, monitoring the RV contractility may aid in identifying isolated right-sided congestion and imminent decompensation.
- Open Access
Case Series Evaluating the Relationship of SGLT2 Inhibition to Pulmonary Artery Pressure and Non-Invasive Cardiopulmonary Parameters in HFpEF/HFmrEF Patients—A Pilot Study
The initiation of sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment was shown to reduce pulmonary artery pressure (PAP) in New York Heart Association (NYHA) class III heart failure (HF) patients with an implanted PAP sensor. We aimed to investigate the impact of SGLT2-I initiation on pulmonary vascular resistance (PVR), pulmonary capillary wedge pressure (PCWP), pulmonary arterial capacitance (PAC), and right ventricle (RV) to PA (RV-PA) coupling in a pilot cohort of HF with preserved/mildly reduced ejection fraction (HFpEF/HFmrEF) patients and whether PVR and PCWP can be serially calculated non-invasively using PAP sensor data during follow-up. Methods: Right heart catheterization parameters (PVR, PCWP, and PAC) were obtained at sensor implantation and echocardiographic assessments (E/E’, RV-PA coupling, and RV cardiac output) were made at baseline and every 3 months. SGLT2 inhibition was initiated after 3 months of telemedical care. Three methods for calculating PVR and PCWP were compared using Bland–Altman plots and Spearman’s correlation. Results: In 13 HF patients (mean age 77 ± 4 years), there were no significant changes in PAP, PVR, PCWP, RV-PA coupling, or PAC over 9 months (all p-values > 0.05), including after SGLT2-I initiation. PVR values were closely correlated across the three methods (PVRNew and PVRNew Tedford (r = 0.614, p < 0.001), PVREcho and PVRNew Tedford (r = 0.446, p = 0.006), and PVREcho and PVRNew (r = 0.394, p = 0.016)), but PCWP methods lacked reliable association (PCWPEcho and PCWPNew (r = 0.180, p = 0.332). Conclusions: No changes in cardiopulmonary hemodynamics were detected after hemodynamic telemonitoring either prior to or following SGLT2-I initiation. Different PVR assessment methods yielded comparable results, whereas PCWP methods were not associated with each other. Further investigations with larger cohorts including repeated right heart catheterization are planned.
Open AccessCase Series Evaluating the Relationship of SGLT2 Inhibition to Pulmonary Artery Pressure and Non-Invasive Cardiopulmonary Parameters in HFpEF/HFmrEF Patients—A Pilot Study
The initiation of sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment was shown to reduce pulmonary artery pressure (PAP) in New York Heart Association (NYHA) class III heart failure (HF) patients with an implanted PAP sensor. We aimed to investigate the impact of SGLT2-I initiation on pulmonary vascular resistance (PVR), pulmonary capillary wedge pressure (PCWP), pulmonary arterial capacitance (PAC), and right ventricle (RV) to PA (RV-PA) coupling in a pilot cohort of HF with preserved/mildly reduced ejection fraction (HFpEF/HFmrEF) patients and whether PVR and PCWP can be serially calculated non-invasively using PAP sensor data during follow-up. Methods: Right heart catheterization parameters (PVR, PCWP, and PAC) were obtained at sensor implantation and echocardiographic assessments (E/E’, RV-PA coupling, and RV cardiac output) were made at baseline and every 3 months. SGLT2 inhibition was initiated after 3 months of telemedical care. Three methods for calculating PVR and PCWP were compared using Bland–Altman plots and Spearman’s correlation. Results: In 13 HF patients (mean age 77 ± 4 years), there were no significant changes in PAP, PVR, PCWP, RV-PA coupling, or PAC over 9 months (all p-values > 0.05), including after SGLT2-I initiation. PVR values were closely correlated across the three methods (PVRNew and PVRNew Tedford (r = 0.614, p < 0.001), PVREcho and PVRNew Tedford (r = 0.446, p = 0.006), and PVREcho and PVRNew (r = 0.394, p = 0.016)), but PCWP methods lacked reliable association (PCWPEcho and PCWPNew (r = 0.180, p = 0.332). Conclusions: No changes in cardiopulmonary hemodynamics were detected after hemodynamic telemonitoring either prior to or following SGLT2-I initiation. Different PVR assessment methods yielded comparable results, whereas PCWP methods were not associated with each other. Further investigations with larger cohorts including repeated right heart catheterization are planned.
- Open Access
- 24 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 11 (2) , 107-108
The untapped potential of guideline-directed heart failure pharmacotherapy: consequences of missed opportunities
Ester J Herrmann, Samuel Sossalla; The Untapped Potential of Guideline-Directed Heart Failure Pharmacotherapy: Consequences of Missed Opportunities, Europe
- 24 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 11 (2) , 107-108
Open AccessThe untapped potential of guideline-directed heart failure pharmacotherapy: consequences of missed opportunities
Ester J Herrmann, Samuel Sossalla; The Untapped Potential of Guideline-Directed Heart Failure Pharmacotherapy: Consequences of Missed Opportunities, Europe
- Open Access
- 7 November 2024
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 115 (3) , 435-448
Association of daily physical activity with pulmonary artery pressure in HFpEF and HFmrEF NYHA class III patients: a pilot trial—feasibility and first results
Introduction: Supervised physical exercise has been shown to benefit patients with heart failure with preserved/mildly reduced ejection fraction (HFpEF/HfmrEF) by improving symptoms and diastolic function. This study aimed to investigate the correlation between unsupervised daily physical activity and changes in daily pulmonary artery pressure (PAP) in patients with stable NYHA class III heart failure (HF) and left ventricular ejection fraction (LVEF) of 45% or higher. Methods: Daily physical activity was monitored over a 3-month period using a Holter-ECG with an accelerometer that calculated an activity-associated, heart rate-derived metabolic equivalent of task (MET) score. PAP was measured using an implanted sensor in 17 patients. Results: During 3 months of PAP monitoring in parallel with Holter ECG in our HF patients (median age 77 [IQR 72–79.5] years, LVEF 55 [49–56] %, mean cardiac index 1.9 ± 0.3), mean, diastolic, and systolic PAP remained unchanged. Patients engaged in unsupervised daily activity with a mean MET score of 5.0 ± 1.2 and a median daily duration of 41 [13–123] minutes. Intensity of daily activity was associated with a higher diastolic PAP on the following day (R 2 = 0.017, p = 0.003), particularly in female patients and those with pulmonary hypertension (PH) (female: R 2 = 0.044, p = 0.002; PH: R 2 = 0.024, p = 0.004). Patients with longer daily activity durations had lower systolic and mean PAP (p = 0.038 and p = 0.048) and a similar diastolic PAP (p = 0.053) after 3 months. Conclusions: Tracking changes in daily PAP based on intensity and duration of unsupervised daily activity using implanted sensors and a PocketECG ® is feasible. While daily activity duration was not directly linked to diastolic PAP on the first day after daily activity, intensity, especially in female and PH patients, was associated with increased diastolic PAP. In addition, longer daily activity, rather than higher intensity, might be more important for lowering PAP in the long term. Further research in larger trials is warranted to confirm these findings.
- 7 November 2024
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 115 (3) , 435-448
Open AccessAssociation of daily physical activity with pulmonary artery pressure in HFpEF and HFmrEF NYHA class III patients: a pilot trial—feasibility and first results
Introduction: Supervised physical exercise has been shown to benefit patients with heart failure with preserved/mildly reduced ejection fraction (HFpEF/HfmrEF) by improving symptoms and diastolic function. This study aimed to investigate the correlation between unsupervised daily physical activity and changes in daily pulmonary artery pressure (PAP) in patients with stable NYHA class III heart failure (HF) and left ventricular ejection fraction (LVEF) of 45% or higher. Methods: Daily physical activity was monitored over a 3-month period using a Holter-ECG with an accelerometer that calculated an activity-associated, heart rate-derived metabolic equivalent of task (MET) score. PAP was measured using an implanted sensor in 17 patients. Results: During 3 months of PAP monitoring in parallel with Holter ECG in our HF patients (median age 77 [IQR 72–79.5] years, LVEF 55 [49–56] %, mean cardiac index 1.9 ± 0.3), mean, diastolic, and systolic PAP remained unchanged. Patients engaged in unsupervised daily activity with a mean MET score of 5.0 ± 1.2 and a median daily duration of 41 [13–123] minutes. Intensity of daily activity was associated with a higher diastolic PAP on the following day (R 2 = 0.017, p = 0.003), particularly in female patients and those with pulmonary hypertension (PH) (female: R 2 = 0.044, p = 0.002; PH: R 2 = 0.024, p = 0.004). Patients with longer daily activity durations had lower systolic and mean PAP (p = 0.038 and p = 0.048) and a similar diastolic PAP (p = 0.053) after 3 months. Conclusions: Tracking changes in daily PAP based on intensity and duration of unsupervised daily activity using implanted sensors and a PocketECG ® is feasible. While daily activity duration was not directly linked to diastolic PAP on the first day after daily activity, intensity, especially in female and PH patients, was associated with increased diastolic PAP. In addition, longer daily activity, rather than higher intensity, might be more important for lowering PAP in the long term. Further research in larger trials is warranted to confirm these findings.
- Open Access
- 24 June 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (6) , e24304
Randomized Pilot Trial of Pre‐ and Postoperative Heart Failure Nurse‐Supported Care in Heart Failure Patients Requiring Noncardiac Surgery—Feasibility and Results
Introduction: The perioperative cardiovascular management of patients undergoing noncardiac surgery is particularly challenging in those with pre‐existing heart failure (HF). This study was designed to evaluate the effectiveness of nurse‐based pre‐ and postoperative specialized HF management in reducing postoperative HF‐associated complications in patients with known HF undergoing noncardiac surgery.Methods: This prospective, randomized pilot study included patients with established HF requiring intermediate‐ to high‐risk noncardiac surgery. Patients received postoperatively either standard care (control group, CG) or nurse‐supported HF management (intervention group, IG). The primary endpoint was a composite of HF‐related postoperative complications at 30 days. Secondary endpoints included length on intensive care unit, length of hospital stay, death, hospitalization for HF, and quality of life assessment using the SF‐12 questionnaire.Results: The trial was halted prematurely for futility. A total of 34 patients (median age 70.5 [IQR 67–75] years; with 15 HfpEF, 9 HfmrEF,10 HfrEF), with an average NT‐proBNP of 1.413 [463–2.832] pg/mL were included. The IG had a lower rate of postoperative primary events (25%; n = 4) compared with the CG (33%; n = 6). There were no differences in secondary endpoints between the groups. Quality‐of‐life scores improved slightly in both groups (δ 5.6 ± 0.9 [CG] and 3.1 ± 1.2 [IG]).Conclusion: Nurse‐based pre‐ and postoperative HF care appears to be feasible and may reduce HF‐associated complications in patients undergoing noncardiac surgery. Larger clinical trials are needed to further evaluate the effectiveness of this approach in reducing postoperative complications in this high‐risk patient population.
- 24 June 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (6) , e24304
Open AccessRandomized Pilot Trial of Pre‐ and Postoperative Heart Failure Nurse‐Supported Care in Heart Failure Patients Requiring Noncardiac Surgery—Feasibility and Results
Introduction: The perioperative cardiovascular management of patients undergoing noncardiac surgery is particularly challenging in those with pre‐existing heart failure (HF). This study was designed to evaluate the effectiveness of nurse‐based pre‐ and postoperative specialized HF management in reducing postoperative HF‐associated complications in patients with known HF undergoing noncardiac surgery.Methods: This prospective, randomized pilot study included patients with established HF requiring intermediate‐ to high‐risk noncardiac surgery. Patients received postoperatively either standard care (control group, CG) or nurse‐supported HF management (intervention group, IG). The primary endpoint was a composite of HF‐related postoperative complications at 30 days. Secondary endpoints included length on intensive care unit, length of hospital stay, death, hospitalization for HF, and quality of life assessment using the SF‐12 questionnaire.Results: The trial was halted prematurely for futility. A total of 34 patients (median age 70.5 [IQR 67–75] years; with 15 HfpEF, 9 HfmrEF,10 HfrEF), with an average NT‐proBNP of 1.413 [463–2.832] pg/mL were included. The IG had a lower rate of postoperative primary events (25%; n = 4) compared with the CG (33%; n = 6). There were no differences in secondary endpoints between the groups. Quality‐of‐life scores improved slightly in both groups (δ 5.6 ± 0.9 [CG] and 3.1 ± 1.2 [IG]).Conclusion: Nurse‐based pre‐ and postoperative HF care appears to be feasible and may reduce HF‐associated complications in patients undergoing noncardiac surgery. Larger clinical trials are needed to further evaluate the effectiveness of this approach in reducing postoperative complications in this high‐risk patient population.
- 10 January 2023
- Published by Springer Nature in Die Innere Medizin
- Vol. 64 (4) , 340-350
Systemische Amyloidoseformen mit kardialer Manifestation
Zusammenfassung Unter dem Terminus Amyloidose werden heterogene Erkrankungen zusammengefasst, bei denen es zur Fehlfaltung von Proteinstrukturen kommt. Diese fehlgefalteten Proteine können sich grundsätzlich im gesamten Körper ablagern und zu Fehlfunktionen in den betroffenen Organen führen. Je nach betroffenem fehlgefaltetem Protein gibt es bevorzugte Ablagerungsstellen. Die kardiale Transthyretin(ATTR) -Amyloidose ist als seltene Ursache einer Kardiomyopathie Teil einer unterdiagnostizierten Systemerkrankung. Für die kardiale ATTR-Amyloidose, bei der es zur Ablagerung von fehlgefaltetem Transthyretin kommt, entweder als Wildtyp (wtATTR) oder als mutierte (mATTR- oder hATTR-)Form, sind seit Kurzem evidenzbasierte Therapiemöglichkeiten mit Verlangsamung der Kardiomyopathieprogression und deutlicher Reduktion der Hospitalisierungsraten verfügbar. Daher ist es wichtig, diese schwerwiegende Erkrankung frühzeitig zu diagnostizieren und von anderen Amyloidosen abzugrenzen. Mithilfe bildgebender Untersuchungen (kardiale MRT oder szintigraphische Verfahren) sowie Immunfixation mit Bestimmung der freien Leichtketten ist ein klinisches Screening einfach möglich, bevor die definitive Diagnose anhand einer Biopsie und/oder genetischen Untersuchung gestellt wird. Eine interdisziplinäre Aufarbeitung bei Verdacht auf eine kardiale Amylodiose unter Einbezug von Hämatoonkologie, Nephrologie, Neurologie und weiteren Disziplinen ist unabdingbar.
- 10 January 2023
- Published by Springer Nature in Die Innere Medizin
- Vol. 64 (4) , 340-350
Systemische Amyloidoseformen mit kardialer Manifestation
Zusammenfassung Unter dem Terminus Amyloidose werden heterogene Erkrankungen zusammengefasst, bei denen es zur Fehlfaltung von Proteinstrukturen kommt. Diese fehlgefalteten Proteine können sich grundsätzlich im gesamten Körper ablagern und zu Fehlfunktionen in den betroffenen Organen führen. Je nach betroffenem fehlgefaltetem Protein gibt es bevorzugte Ablagerungsstellen. Die kardiale Transthyretin(ATTR) -Amyloidose ist als seltene Ursache einer Kardiomyopathie Teil einer unterdiagnostizierten Systemerkrankung. Für die kardiale ATTR-Amyloidose, bei der es zur Ablagerung von fehlgefaltetem Transthyretin kommt, entweder als Wildtyp (wtATTR) oder als mutierte (mATTR- oder hATTR-)Form, sind seit Kurzem evidenzbasierte Therapiemöglichkeiten mit Verlangsamung der Kardiomyopathieprogression und deutlicher Reduktion der Hospitalisierungsraten verfügbar. Daher ist es wichtig, diese schwerwiegende Erkrankung frühzeitig zu diagnostizieren und von anderen Amyloidosen abzugrenzen. Mithilfe bildgebender Untersuchungen (kardiale MRT oder szintigraphische Verfahren) sowie Immunfixation mit Bestimmung der freien Leichtketten ist ein klinisches Screening einfach möglich, bevor die definitive Diagnose anhand einer Biopsie und/oder genetischen Untersuchung gestellt wird. Eine interdisziplinäre Aufarbeitung bei Verdacht auf eine kardiale Amylodiose unter Einbezug von Hämatoonkologie, Nephrologie, Neurologie und weiteren Disziplinen ist unabdingbar.
- Open Access
Pulmonary Artery Pressure-Guided Telemonitoring Reduced Pulmonary Artery Pressure but Did Not Result in Higher Doses of Guideline-Directed Medical Therapy–Observations from an Advanced Elderly German Heart Failure Cohort
Introduction: Remote pulmonary artery pressure (PAP)-guided heart failure (HF) therapy for NYHA class III patients has been shown to reduce hospitalizations and increase survival. We aimed to assess whether PAP monitoring allows for the increase in HF directed medication in an elderly German cohort of advanced HF patients already receiving clinically optimized HF medication. Methods: We analyzed PAP and HF medication dosage, including diuretics, in 24 patients (mean age, 76 years) using implanted PAP-sensors during the first 12 months of PAP-guided HF care in an interdisciplinary HF unit. Results: During 12 months of PAP-guided HF therapy, PAP decreased significantly (△PAP systolic–6 ± 10, △PAP diastolic–4 ± 7, △PAP mean–4 ± 8 mm Hg, p < 0.01 for all). 16% of patients had an unplanned HF hospitalization. There was no significant change over time with respect to the dosage of RAAS inhibitors (ACE-I/ARB/ARNI), Beta blockers, or MRA treatments. In contrast, the dosage of loop diuretics increased significantly (2.1 ± 0.5-fold) over time. In the comparison of a “responder” (patients with PAP and diuretic dose decline) and “non-responder” (patients with PAP and diuretic dose increase) group, there were no significant differences between any of the baseline, medication, or HF hospitalization characteristics between the two groups. Conclusions: In elderly patients treated with clinically optimized HF medication, no further evidence-based medication increase could be achieved using PAP-guided HF care. However, by individual adjustment of diuretic dosage, a significant decline in PAP over time occurred, which could not be predicted by any of the baseline characteristics.
Open AccessPulmonary Artery Pressure-Guided Telemonitoring Reduced Pulmonary Artery Pressure but Did Not Result in Higher Doses of Guideline-Directed Medical Therapy–Observations from an Advanced Elderly German Heart Failure Cohort
Introduction: Remote pulmonary artery pressure (PAP)-guided heart failure (HF) therapy for NYHA class III patients has been shown to reduce hospitalizations and increase survival. We aimed to assess whether PAP monitoring allows for the increase in HF directed medication in an elderly German cohort of advanced HF patients already receiving clinically optimized HF medication. Methods: We analyzed PAP and HF medication dosage, including diuretics, in 24 patients (mean age, 76 years) using implanted PAP-sensors during the first 12 months of PAP-guided HF care in an interdisciplinary HF unit. Results: During 12 months of PAP-guided HF therapy, PAP decreased significantly (△PAP systolic–6 ± 10, △PAP diastolic–4 ± 7, △PAP mean–4 ± 8 mm Hg, p < 0.01 for all). 16% of patients had an unplanned HF hospitalization. There was no significant change over time with respect to the dosage of RAAS inhibitors (ACE-I/ARB/ARNI), Beta blockers, or MRA treatments. In contrast, the dosage of loop diuretics increased significantly (2.1 ± 0.5-fold) over time. In the comparison of a “responder” (patients with PAP and diuretic dose decline) and “non-responder” (patients with PAP and diuretic dose increase) group, there were no significant differences between any of the baseline, medication, or HF hospitalization characteristics between the two groups. Conclusions: In elderly patients treated with clinically optimized HF medication, no further evidence-based medication increase could be achieved using PAP-guided HF care. However, by individual adjustment of diuretic dosage, a significant decline in PAP over time occurred, which could not be predicted by any of the baseline characteristics.
- 15 March 2022
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 147 (06) , 326-331
Neue europäische Herzinsuffizienz-Leitlinie 2021 – Paradigmenwechsel in der Therapie
Was ist neu?: Neuer medikamentöser Therapie-Algorithmus für Herzinsuffizienz mit LVEF ≤ 40 % Für Herzinsuffizienz mit reduzierter Pumpfunktion ≤ 40 % (HFrEF) empfehlen die neuen Herzinsuffizienz-Leitlinien 2021 der ESC einen grundlegend neuen Behandlungsalgorithmus. Dieser sieht vor, dass alle 4 letalitätssenkenden Substanzen (ARNI oder ACE-Hemmer, Betablocker, MRA und SGLT-2-Inhibitoren) so früh wie möglich gegeben werden. Das konventionelle Stufenschema mit schrittweiser Erhöhung wird nicht mehr empfohlen. Empfehlungen für HfpEF Vereinfacht wurde der Diagnose-Algorithmus für die HFpEF, der nun neben Symptomen und Zeichen einer Herzinsuffizienz, einer LVEF ≥ 50 % zusätzlich objektive Kriterien für eine strukturelle und/oder funktionelle Auffälligkeit mit diastolischer Dysfunktion und erhöhten Füllungsdrücken fordert sowie erhöhte natriuretische Peptide. Für die Behandlung der HFpEF gibt es keine Veränderungen im Vergleich zu 2016, jedoch ist hier eine kurzfristige Überarbeitung der Leitlinie zu erwarten. Bedeutung ausgewählter Begleit-Erkrankungen Die primäre Empfehlung bei Vorhofflimmern ist die Antikoagulation mittels NOAK. Der Stellenwert der PVI ist aufgewertet worden. Die Entscheidung zur Transkatheter-Therapie einer sekundären Mitralklappen-Insuffizienz sollte bei Vorliegen entsprechender Kriterien im Heartteam getroffen werden. Fortgeschrittene Herzinsuffizienz Für die Diagnose einer fortgeschrittenen Herzinsuffizienz wurden 4 Kriterien definiert. Diese umfassen schwere und persistierende Symptome NYHA III oder IV, den Nachweis einer schweren kardialen Dysfunktion, Episoden von Stauung, die mittels i. v. Diuretika und/oder Inotropika behandelt werden müssen, maligne Arrhythmien und eine schwere Einschränkung der Belastungskapazität. Für diese Patienten gibt es einen neuen Behandlungsalgorithmus, in welchem der Stellenwert der mechanischen Kreislaufunterstützung aufgewertet wurde. Akute Herzinsuffizienz Für Patienten mit akuter Herzinsuffizienz wird nach der Entlassung aus der stationären Behandlung eine Einbindung in ein „Disease Management Program“ und in ein multimodales, multiprofessionelles Therapiekonzept empfohlen.
- 15 March 2022
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 147 (06) , 326-331
Neue europäische Herzinsuffizienz-Leitlinie 2021 – Paradigmenwechsel in der Therapie
Was ist neu?: Neuer medikamentöser Therapie-Algorithmus für Herzinsuffizienz mit LVEF ≤ 40 % Für Herzinsuffizienz mit reduzierter Pumpfunktion ≤ 40 % (HFrEF) empfehlen die neuen Herzinsuffizienz-Leitlinien 2021 der ESC einen grundlegend neuen Behandlungsalgorithmus. Dieser sieht vor, dass alle 4 letalitätssenkenden Substanzen (ARNI oder ACE-Hemmer, Betablocker, MRA und SGLT-2-Inhibitoren) so früh wie möglich gegeben werden. Das konventionelle Stufenschema mit schrittweiser Erhöhung wird nicht mehr empfohlen. Empfehlungen für HfpEF Vereinfacht wurde der Diagnose-Algorithmus für die HFpEF, der nun neben Symptomen und Zeichen einer Herzinsuffizienz, einer LVEF ≥ 50 % zusätzlich objektive Kriterien für eine strukturelle und/oder funktionelle Auffälligkeit mit diastolischer Dysfunktion und erhöhten Füllungsdrücken fordert sowie erhöhte natriuretische Peptide. Für die Behandlung der HFpEF gibt es keine Veränderungen im Vergleich zu 2016, jedoch ist hier eine kurzfristige Überarbeitung der Leitlinie zu erwarten. Bedeutung ausgewählter Begleit-Erkrankungen Die primäre Empfehlung bei Vorhofflimmern ist die Antikoagulation mittels NOAK. Der Stellenwert der PVI ist aufgewertet worden. Die Entscheidung zur Transkatheter-Therapie einer sekundären Mitralklappen-Insuffizienz sollte bei Vorliegen entsprechender Kriterien im Heartteam getroffen werden. Fortgeschrittene Herzinsuffizienz Für die Diagnose einer fortgeschrittenen Herzinsuffizienz wurden 4 Kriterien definiert. Diese umfassen schwere und persistierende Symptome NYHA III oder IV, den Nachweis einer schweren kardialen Dysfunktion, Episoden von Stauung, die mittels i. v. Diuretika und/oder Inotropika behandelt werden müssen, maligne Arrhythmien und eine schwere Einschränkung der Belastungskapazität. Für diese Patienten gibt es einen neuen Behandlungsalgorithmus, in welchem der Stellenwert der mechanischen Kreislaufunterstützung aufgewertet wurde. Akute Herzinsuffizienz Für Patienten mit akuter Herzinsuffizienz wird nach der Entlassung aus der stationären Behandlung eine Einbindung in ein „Disease Management Program“ und in ein multimodales, multiprofessionelles Therapiekonzept empfohlen.
- Open Access
- 10 October 2018
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 29 (4) , 393-400
Pulmonalarterieller Drucksensor zur ambulanten Beurteilung des ventrikulären Füllungsdrucks bei fortgeschrittener Herzinsuffizienz
Patienten mit fortgeschrittener Herzinsuffizienz leiden unter wiederholten Hospitalisierungen. Nichtinvasives hämodynamisches Telemonitoring zur Bestimmung des pulmonalvaskulären Füllungsdrucks kann Hospitalisierungen reduzieren. In diesem Beitrag wird über mögliche Kontrollintervalle und Standardisierung in der Nachsorge des hämodynamischen Telemonitorings berichtet.
- 10 October 2018
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 29 (4) , 393-400
Open AccessPulmonalarterieller Drucksensor zur ambulanten Beurteilung des ventrikulären Füllungsdrucks bei fortgeschrittener Herzinsuffizienz
Patienten mit fortgeschrittener Herzinsuffizienz leiden unter wiederholten Hospitalisierungen. Nichtinvasives hämodynamisches Telemonitoring zur Bestimmung des pulmonalvaskulären Füllungsdrucks kann Hospitalisierungen reduzieren. In diesem Beitrag wird über mögliche Kontrollintervalle und Standardisierung in der Nachsorge des hämodynamischen Telemonitorings berichtet.